Arsenic trioxide: A promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice.
about
Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS)How I treat autoimmune lymphoproliferative syndromeLow-Concentration Arsenic Trioxide Inhibits Skeletal Myoblast Cell Proliferation via a Reactive Oxygen Species-Independent PathwayUpdated Understanding of Autoimmune Lymphoproliferative Syndrome (ALPS).Generation of gene-engineered chimeric DNA molecules for specific therapy of autoimmune diseases.Differential oxidative modification of proteins in MRL+/+ and MRL/lpr mice: Increased formation of lipid peroxidation-derived aldehyde-protein adducts may contribute to accelerated onset of autoimmune response.Immunotoxicity and biodistribution analysis of arsenic trioxide in C57Bl/6 mice following a 2-week inhalation exposureLoss of P2X7 receptor plasma membrane expression and function in pathogenic B220+ double-negative T lymphocytes of autoimmune MRL/lpr mice.Sensitivity of leukemic T-cell lines to arsenic trioxide cytotoxicity is dependent on the induction of phosphatase B220/CD45R expression at the cell surface.Significantly reduced lymphadenopathy, salivary gland infiltrates and proteinuria in MRL-lpr/lpr mice treated with ultrasoluble curcumin/turmeric: increased survival with curcumin treatmentDistinct metabolic programs in activated T cells: opportunities for selective immunomodulation.Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr miceValproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas -deficient MRL/lpr(-/-) murine model of autoimmune lymphoproliferative syndrome (ALPS)Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease.Apoptotic signaling activated by modulation of the F0F1-ATPase: implications for selective killing of autoimmune lymphocytes.Arsenic trioxide and other arsenical compounds inhibit the NLRP1, NLRP3, and NAIP5/NLRC4 inflammasomes.Advances in autoimmune lymphoproliferative syndromes.Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus.The combination of arsenic and cryptotanshinone induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in breast cancer cells.An Update on the Use of Immunomodulators in Primary Immunodeficiencies.Anticancer activity in human multiple myeloma U266 cells: synergy between cryptotanshinone and arsenic trioxide.Arsenic trioxide prevents nitric oxide production in lipopolysaccharide -stimulated RAW 264.7 by inhibiting a TRIF-dependent pathway.Bortezomib treatment induces a higher mortality rate in lupus model mice with a higher disease activity.Autophagy plays a protective role as an anti-oxidant system in human T cells and represents a novel strategy for induction of T-cell apoptosis.Multidrug resistance protein 1 (ABCC1) confers resistance to arsenic compounds in human myeloid leukemic HL-60 cells.Targeting Notch signaling in autoimmune and lymphoproliferative disease.Characterization of the metabolic phenotype of chronically activated lymphocytes.Inhibition of angiogenesis by arsenic trioxide via TSP-1-TGF-β1-CTGF-VEGF functional module in rheumatoid arthritis.Effects of Arsenic Trioxide on INF-gamma Gene Expression in MRL/lpr Mice and Human Lupus.Effects of tetra-arsenic tetra-sulfide on BXSB lupus-prone mice: a pilot study.Arsenic trioxide alleviates airway hyperresponsiveness and promotes apoptosis of CD4+ T lymphocytes: evidence for involvement of the ER stress-CHOP pathway.Transforming Growth Factor-β and Interleukin-10 Synergistically Regulate Humoral Immunity via Modulating Metabolic Signals.Reactive oxygen species-mediated killing of activated fibroblasts by arsenic trioxide ameliorates fibrosis in a murine model of systemic sclerosisMercury and arsenic attenuate canonical and non-canonical NLRP3 inflammasome activation
P2860
Q24623371-95460A13-AC8D-4010-9BBE-CB56E0866F1DQ24633207-699A355B-FD8A-4384-BCC4-C72CE1EE2C19Q28388442-56DF10BA-40E9-44FE-BFCB-BFD962ED9AB7Q33420245-09C9CD67-7256-4444-933D-DC4E2D158D7CQ33586280-F426203A-7198-4074-9AE6-60A628C84496Q33691818-33D7AB2B-589B-4D52-9693-277FC9265E1CQ33745817-785F5B29-20FF-46A9-958E-B9EFC5D738A9Q34533196-35C31332-544D-46AD-AAD7-AE92B7DF61F4Q34611982-38883D73-6937-48BB-BD69-F2BC2FCD2DF3Q36053818-4AE1F121-A8B9-443F-9AA8-92EEE33673D3Q36174985-9095491F-85BB-4AD6-AF51-163B9678049FQ36254552-80EB5226-AB1E-4E92-B447-41D7B79A383FQ37219274-79525267-0AFD-4EE7-90AB-CA9681AC4BE3Q37248354-EBD908CA-2C1C-43FD-9671-AEDED604A680Q37416439-A1D535B4-737D-4544-8643-29FC3E7AF978Q37449578-716AC43C-3E5F-4146-8135-AA5427A2E2D7Q37859077-E420A6D8-C729-4FFD-BA92-E7402F842E74Q38903851-8D2D3DA0-193D-433F-A62A-6A5A23AA859FQ38938902-B7759951-4AAA-4030-AFE8-4C3CBA77A350Q39016299-F6EB7DD4-C96E-45F2-9E85-927E6F2E4FBFQ39175673-C4B6FC45-65E8-48CE-8C13-FAFFEC7071F2Q39252319-C29CB28F-D08D-4CFD-B39F-DCC36CC359B6Q41363502-5CEB742D-DB23-41FC-98A6-A35592B40DADQ42220520-F821A584-3418-47FF-8D1D-CD25B860DAAFQ42715412-E5B878F2-F615-47A1-9592-B131D53BF55CQ42953771-11E54997-C494-4CC1-8B3E-5F5893CC50AFQ42963724-15AC0284-F970-4233-A223-718182E76C06Q47164886-85DA1815-C5E8-42B0-B2E4-E6EED3BA9434Q47380191-4B2C9AA5-DCD1-4B05-9892-6944398DAAE7Q47770126-CE8BD4FD-917A-4441-BC89-27B8FC2D4A5BQ47776181-77141475-037A-40CB-BC85-A817999766CBQ55411306-51F56ABA-47F8-4CED-8AB5-5DDB8DEADE8BQ58003935-E8238866-1B2F-4490-B066-6D9265DC586DQ58747603-40A6546A-0256-4617-8A71-F265ADE74370
P2860
Arsenic trioxide: A promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice.
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Arsenic trioxide: A promising ...... une syndromes in MRL/lpr mice.
@ast
Arsenic trioxide: A promising ...... une syndromes in MRL/lpr mice.
@en
Arsenic trioxide: A promising ...... une syndromes in MRL/lpr mice.
@nl
type
label
Arsenic trioxide: A promising ...... une syndromes in MRL/lpr mice.
@ast
Arsenic trioxide: A promising ...... une syndromes in MRL/lpr mice.
@en
Arsenic trioxide: A promising ...... une syndromes in MRL/lpr mice.
@nl
prefLabel
Arsenic trioxide: A promising ...... une syndromes in MRL/lpr mice.
@ast
Arsenic trioxide: A promising ...... une syndromes in MRL/lpr mice.
@en
Arsenic trioxide: A promising ...... une syndromes in MRL/lpr mice.
@nl
P2093
P1433
P1476
Arsenic trioxide: A promising ...... une syndromes in MRL/lpr mice.
@en
P2093
Danielle Bonardelle
Mounira K Chelbi-Alix
Pierre Bobé
P304
P356
10.1182/BLOOD-2006-04-020610
P407
P577
2006-08-22T00:00:00Z